MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.170
+0.060
+2.84%
After Hours: 2.150 -0.02 -0.92% 19:59 08/07 EDT
OPEN
2.150
PREV CLOSE
2.110
HIGH
2.200
LOW
2.100
VOLUME
11.51M
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
0.1950
MARKET CAP
291.10M
P/E (TTM)
-4.0380
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HTBX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

HTBX News

More
Heat Bio +4% on Q2 results; advances development plans for COVID-19 vaccine
Seeking Alpha - Article · 23h ago
2 Risky Coronavirus Vaccine Stocks That Could Make You Filthy Rich
Motley Fool · 4d ago
Heat Biologics, Inc. (NASDAQ:HTBX) Analysts Just Slashed This Year's Revenue Estimates By 12%
Simply Wall St. · 07/30 14:07
QCOM, UPS among premarket gainers
Seeking Alpha - Article · 07/30 12:24
Why Heat Biologics Stock Is Spiking Today
Motley Fool · 07/29 17:05
Sonoma Pharmaceuticals leads healthcare gainers; Aphria and Soligenix among losers
Seeking Alpha · 07/29 15:00
AMD, SHOP among premarket gainers
Seeking Alpha - Article · 07/29 12:20
Heat Biologics COVID-19 vaccine shows encouraging action in preclinical study
Seeking Alpha - Article · 07/29 11:59

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About HTBX

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
More

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTBX stock methods without spending real money on the virtual paper trading platform.